Li Jindan, Fu Chaojiang, Zhao Sheng, Pu Yongzhu, Yang Fake, Zeng Shuguang, Yang Conghui, Gao Hongqiang, Chen Long
Department of PET-CT/MR Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Department of Emergency, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, Yunnan, China.
Front Oncol. 2023 Apr 28;13:920896. doi: 10.3389/fonc.2023.920896. eCollection 2023.
Recently, the morbidity and mortality of pancreatic cancer have been increasing year by year. Because of its deep anatomical location and because most presented patients often suffer from abdominal pain or jaundice, it is difficult to diagnose pancreatic cancer at an early stage, leading to late clinical stage and poor prognosis. integrated positron emission tomography/magnetic resonance imaging (PET/MRI) fusion imaging not only has the characteristics of high resolution and multi-parameter imaging of MRI, but also combines the high sensitivity and the semi-quantitative characteristics of PET. In addition, the continuous development of novel MRI imaging and PET imaging biomarkers provide a unique and precise research direction for future pancreatic cancer research. This review summarizes the value of PET/MRI in the diagnosis, staging, efficacy monitoring, and prognosis evaluation of pancreatic cancer, and prognosis for developing emerging imaging agents and artificial intelligence radiomics in pancreatic cancer.
近年来，胰腺癌的发病率和死亡率逐年上升。由于其解剖位置较深，且大多数就诊患者常伴有腹痛或黄疸，胰腺癌早期难以诊断，导致临床分期较晚，预后较差。正电子发射断层扫描/磁共振成像（PET/MRI）融合成像不仅具有MRI的高分辨率和多参数成像特点，还结合了PET的高灵敏度和半定量特征。此外，新型MRI成像和PET成像生物标志物的不断发展为未来胰腺癌研究提供了独特而精确的研究方向。本文综述了PET/MRI在胰腺癌诊断、分期、疗效监测和预后评估中的价值，以及在开发胰腺癌新型成像剂和人工智能放射组学方面的前景。
